The Pharmaceutical Filtration Market is experiencing steady growth driven by rising biologics production, stringent ...

The MarketWatch News Department was not involved in the creation of this content. Bozen, Italy--(Newsfile Corp. - December 5, 2025) - Transfeero ends 2025 as one of the strongest years in its history, ...

Nationwide law firm Pepperells Solicitors has agreed an acquisition deal with Seaham-based Michael Cook Law Firm Limited, marking the company’s second strategic purchase in only eight weeks. Did you ...

Major pharmaceutical companies are cutting drug discovery timelines by 30% or more through AI models that predict molecular ...

Omnicom has closed its acquisition of rival Interpublic in an all-stock deal reshaping the advertising and marketing sectors and creating the world’s largest ad holding company. The combined company, ...

There are many ways to grow your business. You can sell a new product, court a new type of customer, or expand into new ...

The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with ...

The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to ...

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few years. In the meantime, the company's performance leaves a lot to be desired.

Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection.